In Conversation
Since 2013, pharmaceutical and biotech company Eleusis has been working to transform psychedelics into modern medicines. For general counsel Paul Slattery, the rise of legal tech has been a mind-enhancing experience.
At Eleusis, we are developing psychedelics for potential therapeutic applications, as well as a care delivery platform that aims to increase the safety, tolerability, and accessibility of any ultimately-approved psychedelic drug therapies. It is a complex path from drug discovery, to preclinical work, to trial design and regulatory submissions, involving selection of potential patient populations, invention of patient monitoring systems, and optimisation of treatment regimes.
Your limit of 1 article in 30 days is up. Please login for full access or subscribe.
Corporate users - click here for simple access (no password needed).
For more information, please contact jasmine.glass@legalbusiness.co.uk
